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Abstract
Aim: To assess the proportion of patients receiving pharmacological therapy for secondary prevention after an acute
coronary syndrome (ACS) in Portugal and to identify age and sex inequalities.
Design: Retrospective cohort study.
Methods: We studied 747 episodes of ST-segment elevation myocardial infarction (STEMI) and 1364 of non-ST-segment
elevation ACS (NSTE-ACS), within a sample of ACS cases consecutively discharged from 10 Portuguese hospitals, in
2008–2009. We estimated adjusted odds ratios (OR) for the association of age and sex with the use of each pharma-
cological treatment.
Results: In STEMI and NSTE-ACS patients, the proportion of patients discharged with aspirin was 96 and 88%,
clopidogrel 91 and 78%, aspirinþclopidogrel 88 and 71%, beta-blockers 80 and 76%, angiotensin-converting enzyme
(ACE) inhibitors/ARB 82 and 80%, statins 93 and 90%, 3-drug (aspirin/clopidogrelþbeta-blockerþstatin) 76 and 69%, and
5-drug treatment (aspirinþclopidogrelþbeta-blockerþACE inhibitor/ARBþstatin) 61 and 48%, respectively. Among
STEMI patients, those aged 80 years were substantially less often discharged with clopidogrel (OR 0.22, 95% confidence
interval, CI, 0.08–0.56), aspirinþclopidogrel (OR 0.34, 95% CI 0.15–0.76), beta-blockers (OR 0.39, 95% CI 0.18–0.82),
3-drug (OR 0.41, 95% CI 0.21–0.83), and 5-drug treatments (OR 0.44, 95% CI 0.23–0.83) than those <60 years; women
were less likely to be discharged with aspirinþclopidogrel (OR 0.52, 95% CI 0.29–0.91). Among NSTE-ACS patients,
those aged 80 years were much less likely to be discharged with beta-blockers (OR 0.58, 95% CI 0.36–0.93), statins
(OR 0.35, 95% CI 0.19–0.64), and 3-drug treatment (OR 0.47, 95% CI 0.30–0.75); sex had no significant effect on
treatment prescription.
Conclusions: The vast majority of younger patients were discharged on evidence-based secondary preventive medi-
cations, but only half received the 5-drug combination. Recommended therapies were substantially underprescribed in
older patients.
Keywords
Acute coronary syndrome, age, inequalities, secondary prevention, sex
Received 6 February 2013; accepted 28 May 2013
Introduction
Ischaemic heart disease remains a leading cause of
death worldwide and in Portugal.1,2 Acute coronary
syndrome (ACS) is the most prevalent manifestation
of unstable ischaemic heart disease and can lead to
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life-threatening complications after the acute phase.
A combination of evidence-based secondary preventive
medications and lifestyle interventions can substantially
reduce that risk. However, these management strategies
need to be considered and implemented at hospital dis-
charge for all ACS survivors, regardless of age or sex.3,4
Age is associated with a higher risk of atheroscler-
otic diseases, due to the degenerative process associated
with aging per se, together with the cumulative impact
of the worsening risk-factor profile. In Portugal, the
proportion of people aged over 65 years almost
doubled from 1980 to 2010.5 Patients with a first non-
fatal ACS have an almost 10% risk of death within
6 months and advanced age is one of the most powerful
independent predictors of death.6 In 2000, 27% of the
individuals admitted to public Portuguese hospitals
with an acute myocardial infarction were aged over
75 years, while in 2008 this proportion increased to
35%.7 Case fatality in these older patients is over
twice that in those aged under 75 years.6
Women have traditionally been seen as a low-risk
population for cardiovascular diseases. However, the
incidence of cardiovascular diseases in women increases
rapidly after menopause to levels similar to those
observed in older men.8 Thus in Portugal, in 2010,
over 18,000 women and 15,000 men died from cardio-
vascular diseases.9 Women now account for over one-
third of acute myocardial infarction cases.7
Furthermore, the age-adjusted prognosis after an
ACS admission is worse in women than in men, pos-
sibly reflecting delays in diagnosis, more frequent atyp-
ical presentation, and crucially less aggressive
treatment.10
Many studies have reported an underutilization of
evidence-based treatment in ACS patients discharged
from hospitals, particularly in women and older
patients.11,12 However, data on the use of pharmaco-
logical therapy after an ACS in Portugal are scarce.13
Therefore, we analysed the proportion of patients
receiving pharmacological therapy as secondary pre-
vention after an ACS admission in 10 Portuguese
hospitals, and explored potential age- and sex-
differences.
Methods
The EURopean HOspital Benchmarking by Outcomes
in acute coronary syndrome Processes (EURHOBOP)
project is a multicentre and multinational retrospective
study of patients hospitalized with a final diagnosis of
ACS, consecutively discharged from 70 hospitals in
seven European countries (Finland, France, Germany,
Greece, Italy, Portugal, and Spain). The current ana-
lysis only considers data from patients admitted in the
10 Portuguese hospitals.
The 10 hospitals were a convenience sample of
public hospitals, selected to cover the mainland country
from north to south and east to west, while serving
both urban and rural populations. Participating hos-
pitals are listed in the Supplementary Appendix (avail-
able online). Since we aimed to have hospitals with
different levels of specialization represented in our
sample, we invited hospitals with diverse characteris-
tics, regarding facilities, infrastructure, and human
resources’ specialization. Overall, five hospitals had a
catheterization laboratory, three had a cardiac surgery
department, while one only had a general internal medi-
cine department with no cardiology department or car-
diologists; four were university hospitals; the number of
beds ranged from 280 to 1124.
From each hospital, we obtained a series of 300 con-
secutive patients, independently of the departments
where the patient had been hospitalized. The inclusion
criteria were a discharge diagnosis of myocardial infarc-
tion, with or without ST-segment elevation, or unstable
angina (International Classification of Diseases 10th
revision: I21.0–I21.9 and I20.0). We aimed to study
patients from 2009 but in hospitals whose annual
number of cases was not enough to obtain the 300-
patient sample we extended the recruitment period
backwards to 2008.
The overall sample included a total of 3009 ACS
patients. For this analysis, we excluded patients who
died during hospitalization (8%), who were transferred
to another hospital (11%), and patients with no data on
discharge medication (9%) (Figure 1), leaving 2231 for
analysis. In comparison with patients included in ana-
lysis, those without data on discharge medication were
slightly older (median age 71 vs. 68 years, p< 0.001)
and more frequently had a non-ST-segment elevation
ACS (NSTE-ACS) (74.8 vs. 64.6%, p¼ 0.003).
However, the proportion of men was identical (68.7
vs. 68.7%, p¼ 0. 552).
Data was collected by trained medical record extrac-
tors using a standardized data collection form. The
main source of information was the discharge letter,
and information on emergency room records and
laboratory information systems was accessed, whenever
available. We extracted information on type of diagno-
sis, demographic characteristics, previous medical his-
tory, admission data, procedures used during
hospitalization, severity indicators and complications
during hospitalization, and discharge medication.
All drugs prescribed at discharge were recorded and
classified according to the Anatomical Therapeutic
Chemical Classification System (ATC). The discharge
therapy considered for this analysis was aspirin (ATC
code: B01AC06), clopidogrel (ATC code: B01AC04),
beta-blockers (ATC codes: C07), angiotensin-convert-
ing enzyme (ACE) inhibitors or angiotensin receptor
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blockers (ARB) (ATC codes: C09A, C09B, C09C, and
C09D) and statins (ATC codes: C10AA and C10BA).
Additionally, we computed composite variables for
drug combinations: double antiplatelet therapy with
aspirin and clopidogrel, 3-drug treatment [(aspirin or
clopidogrel) and beta-blocker and statin] and 5-drug
treatment [aspirin and clopidogrel and beta-blocker
and (ACE inhibitor or ARB) and statin].
We used mixed-effects logistic regression to estimate
odds ratios (OR) for the association of age and sex with
the use of each pharmacological treatment. The models
included variables that are likely to influence the
prescription due to their role as compelling indication
or relative contraindication for each drug (see Table 1
footnotes) as fixed effects and random intercept at the
hospital level to account for differences between hos-
pitals. The potentially relevant confounders were iden-
tified based on previous knowledge, independently of
their significant effect in this sample.3,4 The main ana-
lysis presented in this paper was stratified by type of
ACS: ST-segment elevation myocardial infarction
(STEMI) or NSTE-ACS. Those who had non-classifi-
able type of ACS and missing data on that variable
were excluded from this analysis. However, in
3009 ACS Patients
2231 ACS Patients
(2008-2009)
234 deceased
311 transferred to another hospital
233 missing data on discharge medication
110 non classifiable ACS
10 missing data on type of ACS
747 STEMI patients 1364 NSTE-ACS patients
Age [median (interquartile range)]: 70 (59-78)yearsAge [median (interquartile range)]: 63 (53-75)years
Proportion of men: 75% Proportion of men: 63%
Previous history:
myocardial infarction: 11%
hypertension: 59%
diabetes: 21%
smoking: 35%
Previous history:
myocardial infarction: 26%
hypertension: 72%
diabetes: 36%
smoking: 20%
-PCI or thrombolysis during hospitalization: 81% -PCI during hospitalization: 41%
ACS – acute coronary syndrome; NSTE-ACS – non-ST segment elevation acute coronary syndrome; PCI – percutaneous coronary
intervention; STEMI - ST segment elevation myocardial infarction
Figure 1. Flowchart illustrating the sample selection for the present analysis and the main characteristics of the patients, by type of
acute coronary syndrome.
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Supplementary Table 4 (available online) we report the
effect of age and sex in all ACS patients, adjusting for
the type of ACS, beyond other confounders.
The ethics committee of the University of Porto
Medical School and the National Commission for
Data Protection approved the study.
Results
The median age of the 2231 patients was 68 years (range
21–99 years), and 20% were aged over 80 years.
Approximately two-thirds were men (67%), with a
lower median age than women (65 vs. 75 years). Fifty-
two percent of the patients were submitted to a PCI and
1% to coronary artery bypass grafting surgery. Most
patients were admitted with a NSTE-ACS (61%), while
a third (33%) had a STEMI and nearly 5% had a non-
classifiable type of ACS due to either subacute presenta-
tion or left bundle branch block of unknown duration.
Information about the type of ACS was not reported in
0.5% of the patients’ clinical files. Compared to the
NSTE-ACS patients, those admitted with STEMI were
younger and more frequently males and smokers, but less
frequently hypertensive or diabetic and had a lower
prevalence of previous myocardial infarction (Figure 1).
Overall, at discharge, 91.0% of patients had a pres-
cription of aspirin, 81.5% clopidogrel, 76.5% both
aspirin and clopidogrel, 77.6% a beta-blocker, 80.0%
an ACE inhibitor/ARB, 91.3% a statin, 71.4% the 3-
drug treatment, and 51.8% the 5-drug treatment.
Among those with a diagnosis of STEMI, 96.2% of
patients were discharged with aspirin, 91.0% clopido-
grel, 88.5% both aspirin and clopidogrel, 80.5% a beta-
blocker, 81.9% a ACE inhibitor/ARB, 93.3% a statin,
75.6% the 3-drug treatment, and 61.2% the 5-drug
treatment. The corresponding proportions for NSTE-
ACS patients were consistently lower: 88.1% aspirin,
77.7% clopidogrel, 71.4% both aspirin and clopidogrel,
76.2% a beta-blocker, 79.0% a ACE inhibitor/ARB,
90.3% a statin, 69.5% for the 3-drug treatment and
47.9% for the 5-drug treatment.
Considering only patients with a first ACS the pro-
portions were very similar, except for a marginally sig-
nificant difference in clopidogrel use in STEMI patients
(85.0 vs. 91.8%, in patients with and without previous
myocardial infarction, respectively, p¼ 0.05).
Overall, the proportion of patients discharged with
pharmacological treatments was higher in younger
patients for almost all medications (Figure 2, left
hand panel). We observed a difference of more than
20% between the youngest and the oldest patients
(<60 vs. 80 years) in the proportion of STEMI
patients treated with aspirin and clopidogrel (94.2 vs.
72.9%), 3-drug treatment (84.5 vs. 61.5%), and 5-drug
treatment (84.5 vs. 61.5%). Similar differences were
noted among NSTE-ACS patients for clopidogrel
(85.7 vs. 62.6%), aspirin and clopidogrel (81.2 vs.
55.5%), 3-drug treatment (76.1 vs. 55.9%), and 5-
drug treatment (53.9 vs. 31.5%). The sex differences
were smaller than those observed with age (Figure 2,
Figure 2. Proportion of patients discharged with pharmacological treatment after an acute coronary syndrome with or without ST-
segment elevation according to age (left) and sex (right).
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right hand panel). Women were significantly less likely
to receive clopidogrel, aspirin and clopidogrel, and 5-
drug treatment, among STEMI patients; and clopido-
grel and statins, among NSTE-ACS patients.
Table 1 presents the independent associations
between age and sex and the use of each pharmaco-
logical treatment. The detailed tables presenting the
OR for all variables included in the final models are
presented in the Supplementary Appendix. Among
STEMI patients, women were much less likely to be
discharged with aspirin and clopidogrel (OR 0.52).
Compared to patients aged under 60 years, those
aged over 80 years were far less often discharged with
clopidogrel (OR 0.22), aspirin and clopidogrel (OR
0.34), beta-blockers (OR 0.39), statins (OR 0.74), 3-
drug treatment (OR 0.41), and 5-drug treatment (OR
0.44). Among NSTE-ACS patients, patients 80 years
were less likely to be discharged with beta-blockers (OR
0.58), statins (OR 0.35), and 3-drug treatment (OR
0.47), comparing with patients aged <60 years. There
were no significant sex differences in pharmacological
treatment prescribing among NSTE-ACS patients.
When considering only patients with a first ACS, the
independent associations between age and sex and the
use of each pharmacological treatment were very simi-
lar, in both STEMI and NSTE-ACS patients.
Discussion
We report a large sample of consecutive ACS patients
discharged from 10 Portuguese representative hospitals
across 2008 and 2009. A large majority of these patients
were discharged with the main evidence-based pharma-
cological treatments. However, only half received the
recommended 5-drug treatment. Worse still, increasing
age had an independent and powerful adverse effect
on the proportion of patients discharged on effective
therapies.
Approximately 10% of post-ACS patients have a
recurrent event within a year after discharge and mor-
tality after discharge remains relatively high.14
However, pharmacological secondary prevention is
potentially very effective in improving these outcomes,
but only if prescribed.3,4 Decisions on how to manage
individual patients should be based on existing recom-
mendations, taking into account the possible
contraindications and cautions warranted for each
treatment, as well as possible drug interactions. There
is a powerful international consensus that, after having
considered contraindications, all ACS patients should
be discharged on low-dose aspirin, an oral adenosine
diphosphate receptor antagonist, a beta-blocker, and a
lipid-lowering drug.3,4 Furthermore, although the use
of ACE inhibitors in all ACS patients is not unani-
mously accepted,15 the current European guidelines
clearly recommend their prescription at discharge
for all patients.3,4
Despite the universal acceptance of clinical guide-
lines and management tools for ACS, there are geo-
graphic variations in the management of ACS.16
Several studies have reported the proportion of ACS
patients discharged with pharmacological treatment in
European countries, and in general these proportions
were high.16 Estimates from the Euro Heart Survey, an
European programme that included data from 22 coun-
tries and in which Portugal did not participate,
reported that 91% of the ACS patients were discharged
with antiplatelet drugs, 80% with beta-blockers, 71%
with ACE inhibitors, and 78% with statins, at hospital
discharge, in 2006–2007.16 However, the proportions
obtained in most of the existing registries may be over-
estimates, since they may represent higher risk patients,
admitted in cardiology departments, in urban or teach-
ing hospitals with cardiac intensive care units. For
instance in Portugal, the National Registry of Acute
Coronary Syndromes suggested that between 2002
and 2008, approximately 94% of ACS patients
were discharged with aspirin, 52% with aspirin and
clopidogrel, 71% with beta-blockers, 71% with ACE
inhibitors, 87% with statins, and 63% with the com-
bination of aspirin, clopidogrel, beta-blockers, ACE
inhibitors, and statins.13 Our data cannot be directly
compared with those estimates, since that registry
only covers cardiology departments, it does not assure
the consecutiveness of patients within participating cen-
tres and generates estimates not necessarily representa-
tive for age or sex.
In contrast, the diverse settings covered in our study
potentially offer better representativeness of the general
ACS population. Furthermore, the large consecutive
sample of cases within a narrow time span regardless
of the department where they had been hospitalized
provides potentially important new data. Also, the
sample provided unique data on the confounders of
age and sex. While treatment with invasive procedures
may be dependent on hospital facilities such as a cath-
eterization laboratory, the prescription of pharmaco-
logical treatment at discharge only depends on the
medical decision. Thus, any variation in treatment
that persisted after adjusting for the wide range of con-
founders was likely to reflect true inequalities.
Despite the prescription of pharmacological treat-
ment to the vast majority of patients at discharge,
there is still scope for considerable improvement.17 In
order to achieve optimal treatment it is particularly
important to identify which groups of patients are
being undertreated and the underlying reasons.
The major differences according to age suggest that
physicians remain reluctant to prescribe these post-
ACS medications to older patients,18,19 despite the
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strong evidence that the old and very old would obtain
a particularly large absolute benefit.20,21 The general
belief that the elderly are at higher risk of side effects
from pharmacological treatment, such as bleeding with
antiplatelet agents and anticoagulants, hypotension,
bradycardia, and renal failure, may partly explain the
under-prescription of these drugs in this population.
We assessed the effect of age independently of the
main contraindications or variables with a possible
role as compelling indication, and older patients were
undertreated even after adjustment. Despite previous
reports highlighting the need to address age-dependent
inequalities in the quality of care for ACS,22–24 elderly
patients hospitalized with an ACS continue to be dis-
advantaged when compared with younger patients.
These persistent inequalities argue for future studies
of motives and perceived barriers in using these evi-
dence-based treatments, including a comparison
between real and perceived clinical contraindications.
Although most therapeutic guidelines explicitly state
that both sexes should be evaluated and treated in the
same way, women with ACS have been less likely than
men to receive evidence-based treatment in some popu-
lations.25,26 Women with an ACS diagnosis are more
likely to be older than men and to have diabetes, hyper-
tension, heart failure, or other comorbidities.27,28 This
might perhaps justify part of the observed differences.
Fortunately, our study suggests some improvements.
We observe very few sex-differences in discharge medi-
cations after adjusting for the potential confounding
effect of age, comorbidities, and contraindications.
This was the first study to examine treatments after
ACS including consecutive patients recruited in a large
sample of Portuguese hospitals, from whom only 11%
were transferred to other hospitals. To compute the
independent effect of age and sex, we considered the
main confounding variables at the individual level
and the effect of the hospital, using a hierarchical
approach. However, some limitations need to be
acknowledged. Given the retrospective nature of this
study, the validity of the conclusions relies on the
accuracy and completeness of the original documenta-
tion. Although we had information for the most
important variables to address our objectives, we
must recognize that it would be best to have a better
characterization of patient’s socioeconomic position
and other clinical information (for instance, peptic
ulcer, and previous experience with these drugs in the
same patient). It is important to note that this study did
not examine the appropriateness of dosage or adher-
ence rates and, therefore, no inference can be made
on these issues. Patient’s adherence to medications
was not assessed, but our primary focus was on phys-
icians’ prescription patterns, and their compliance to
guidelines. In addition to pharmacological treatment,
lifestyle changes are important in secondary preven-
tion.3,4 Since this information was not described sys-
tematically in the original documentation, we were
not able to assess the extent to which this recommen-
dation was given to the patients. Finally, we had miss-
ing data on discharge medication in 9% of the study
population, and those excluded were significantly older
and more frequently had a NSTE-ACS diagnosis, when
compared with the patients with information on dis-
charge medication. This suggests that the proportions
reported are slightly overestimated when comparing
with the initial sample selected for this study.
In conclusion, the vast majority of patients received
evidence-based pharmacological treatment, but only
half were discharged with the combination of the rec-
ommended five drugs. Further improvements are neces-
sary, especially in elderly patients, in order to reduce
future events and to improve their quality of life.
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